XORTX Therapeutics Completes Manufacturing and Packaging of Clinical Drug Supply for XRX-OXY-102 Trial
XORTX Therapeutics has finalized the manufacturing and packaging of its clinical drug supply for the upcoming XRX-OXY-102 clinical trial.
Stocks · News reference
XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease,
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
XORTX Therapeutics has finalized the manufacturing and packaging of its clinical drug supply for the upcoming XRX-OXY-102 clinical trial.
The Japan Patent Office has issued a decision to grant a patent for XORTX Therapeutics' XRx-101 program, covering compositions and formulations for treating acute kidney injury associated with respiratory viral infections.
XORTX Therapeutics announced that the Japan Patent Office has issued a Decision to Grant a patent for its xanthine oxidase inhibitor compositions (XRx-101) for treating acute kidney injury and other health consequences of viral infections. The patent, expected to remain in force until March 2041, marks the company's first patent protection in Japan and strengthens its intellectual property position in one of the world's largest pharmaceutical markets.
XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.